Kiniksa Pharmaceuticals
KNSA
176 hedge funds and large institutions have $889M invested in Kiniksa Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 60 increasing their positions, 58 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
94% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 18
15% more capital invested
Capital invested by funds: $773M → $889M (+$116M)
10% more funds holding
Funds holding: 160 → 176 (+16)
1.31% more ownership
Funds ownership: 94.01% → 95.32% (+1.3%)
6% more call options, than puts
Call options by funds: $2.7M | Put options by funds: $2.55M
3% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$30.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$23.7M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$15.7M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$13.4M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$9.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$31.3M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$30.7M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$22.5M |
| 4 |
Morgan Stanley
New York
|
-$8.47M |
| 5 |
JP Morgan Chase
New York
|
-$7.44M |
KNSA Hedge Fund Activity: Q1 2025 in Review
176 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2025, worth a combined $889M — up 15% from $773M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new KNSA positions and 18 closed out — a net gain of 17 holders — while 60 added to existing stakes and 58 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $30.7M. The largest seller was HHLR Advisors, exiting entirely with an estimated $31.3M sold.
- 176 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2025, up from 160 in Q4 2024.
- Funds reported $889M of Kiniksa Pharmaceuticals stock for Q1 2025, up 15% quarter-over-quarter.
- 35 funds opened new Kiniksa Pharmaceuticals positions in Q1 2025 and 18 closed out, a net change of +17 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2025 was Tang Capital Management, an estimated $30.7M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2025 was HHLR Advisors, an estimated $31.3M sold.
Based on aggregated 13F filings for Q1 2025.